Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
Kathryn Lanza, Christopher Bishop
Biomedicines (2021) Vol. 9, Iss. 3, pp. 314-314
Open Access | Times Cited: 10

Showing 10 citing articles:

Dopamine Signaling in Substantia Nigra and Its Impact on Locomotor Function—Not a New Concept, but Neglected Reality
Michael F. Salvatore
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1131-1131
Open Access | Times Cited: 13
Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa‐Induced Dyskinesia
Abdolaziz Ronaghi, Tiberiu Loredan Stan, Sebastián A. Barrientos, et al.
European Journal of Neuroscience (2025) Vol. 61, Iss. 5
Open Access
Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosis
Tiberiu Loredan Stan, Abdolaziz Ronaghi, Sebastián A. Barrientos, et al.
Neurotherapeutics (2024) Vol. 21, Iss. 2, pp. e00334-e00334
Open Access | Times Cited: 4
Neuroplasticity in levodopa-induced dyskinesias: An overview on pathophysiology and therapeutic targets
Francesco Bove, Benedetta Angeloni, Pasquale Sanginario, et al.
Progress in Neurobiology (2023) Vol. 232, pp. 102548-102548
Closed Access | Times Cited: 9
Neuroprotective effects of Gypenosides: A review on preclinical studies in neuropsychiatric disorders
Gengfan Liang, Yu Lee, Audrey Siew Foong Kow, et al.
European Journal of Pharmacology (2024) Vol. 978, pp. 176766-176766
Closed Access | Times Cited: 3
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration
Sotirios Grigoriou, Elena Espa, Per Odin, et al.
Neuropharmacology (2023) Vol. 237, pp. 109630-109630
Open Access | Times Cited: 6
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
Peter Jenner, Cristian Falup‐Pecurariu, Valentina Leta, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 11, pp. 1337-1347
Open Access | Times Cited: 4
Decrease of KATP channel expression through D3 receptor-mediated GSK3β signaling alleviates levodopa-induced dyskinesia (LID) in Parkinson's disease mouse model
Yi‐Ying Kuo, Sih-Yu Pen, Chia-Hui Cheng, et al.
Life Sciences (2024) Vol. 359, pp. 123255-123255
Closed Access | Times Cited: 1
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?
Mohammed Alsalmi, Jawad Al‐Kassmy, Woojin Kang, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 25, Iss. 1, pp. 1-3
Open Access | Times Cited: 1
Physiological changes in advanced Parkinson's disease: Altered motor cortical plasticity and its significance in pathophysiology and clinical symptoms
Takahiro Shimizu, Ritsuko Hanajima
Neurology and Clinical Neuroscience (2023) Vol. 11, Iss. 4, pp. 218-225
Closed Access
Page 1

Scroll to top